View Older Stories View More Recent Stories
-
Morgan Stanley Reiterates Overweight Rating on Biohaven Pharmaceutical Holding (BHVN)
-
TD Cowen on Biohaven Pharmaceutical Holding (BHVN): 'This Pipeline Is Impressive', 'Buy BHVN'
-
Biohaven Pharma (BHVN) Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day
-
Biohaven Pharma (BHVN) Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates
-
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $54 at RBC Capital
-
Biohaven Pharma (BHVN) Misses Q1 EPS by 47c
-
Biohaven Pharma (BHVN) Announces Investment up to $600 Million by Oberland Capital
-
Biohaven Pharma (BHVN) call put ratio 2 call to 1 put with a focus on May calls
-
Biohaven Pharma (BHVN) Halted on Volatility Down 18%
-
Biohaven Pharma (BHVN) Withdraws Application For Troriluzole In EU
-
Increasing unusual call option volume: XND HTZ UMC BHVN UMC AMCR HDB AEVA NICE FTI
-
Bernstein Recommends Three US Biotech Stocks Amid 'Heightened Regulatory Uncertainty'
-
Avalo Therapuetics (AVTX) Appoints Michael Heffernan as Chairman of the Board
-
Cantor Fitzgerald says 15% of biotech companies down 40% or more
-
Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
-
Piper Sandler on Biohaven Pharmaceutical Holding (BHVN): 'Industry-Leading Pipeline Continues to Mature'
-
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $63 at Morgan Stanley
-
H.C. Wainwright Reiterates Buy Rating on Biohaven Pharmaceutical Holding (BHVN)
-
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $63 at Jefferies
-
TD Cowen on Biohaven Pharmaceutical Holding (BHVN): 'BHV-1300 Is Crushing Its Target'
-
RBC on Biohaven Pharmaceutical Holding (BHVN): 'Stock Reaction Overdone On Bipolar Miss'
-
Bernstein: 'Still like Biohaven Pharmaceutical Holding (BHVN) Stock but No Longer a Top Pick'; PT Lowered
-
Biohaven Pharma (BHVN) Misses Q4 EPS by 11c
-
Piper Sandler Reiterates Overweight Rating on Biohaven Pharmaceutical Holding (BHVN)
-
Biohaven Pharma (BHVN) Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300
-
Biohaven Pharma (BHVN) Announces FDA Acceptance and Priority Review of Troriluzole NDA
-
Deutsche Bank Starts Biohaven Pharmaceutical Holding (BHVN) at Buy
-
Cantor Fitzgerald provides update on Biotechnology stocks
-
RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
-
Bernstein's top two SMID biotech picks for 2025
-
H.C. Wainwright Reiterates Buy Rating on Biohaven Pharmaceutical Holding (BHVN)
-
Bernstein on Biohaven Pharmaceutical Holding (BHVN): 'BHVN Remains One of Our Top Picks'
-
Biohaven Pharma (BHVN) Reports Positive Phase 1 Degrader Data
-
Biohaven Pharma (BHVN) Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates
-
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $61 at RBC Capital
-
Here are the key catalysts for 3 US biotech stocks into year end
-
Is Trump 2.0 good or bad for healthcare stocks?
-
Baird Reiterates Outperform Rating on Biohaven Pharmaceutical Holding (BHVN)
-
Piper Sandler Reiterates Overweight Rating on Biohaven Pharmaceutical Holding (BHVN)
-
Biohaven Pharma (BHVN) Falls 13% Following Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity
-
Biohaven Pharma (BHVN) Provides Update on Taldefgrobep Alfa Development Program
-
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $75 at TD Cowen
-
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $66 at RBC Capital
-
Biohaven Pharma (BHVN) Misses Q3 EPS by 4c
-
BofA Securities Reiterates Buy Rating on Biohaven Pharmaceutical Holding (BHVN)
-
Leerink Partners Reiterates Outperform Rating on Biohaven Pharmaceutical Holding (BHVN)
-
BTIG Reiterates Buy Rating on Biohaven Pharmaceutical Holding (BHVN)
-
Baird Reiterates Outperform Rating on Biohaven Pharmaceutical Holding (BHVN)
-
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $63 at BofA Securities
-
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $68 at JPMorgan

